前列腺MRI/超声融合引导活检对放疗推荐的影响
本研究纳入2008年1月至2016年1月在同一机构接受放疗并同时行标准超声引导活检(SOC-Bx)和MRI/超声融合引导活检(MRI-Bx)的73例患者,评估MRI-Bx对放疗和雄激素剥夺治疗(ADT)推荐的影响。结果显示MRI-Bx较既往SOC-Bx显著提高Gleason评分7和8-10的比例,并将极高危患者比例从24.7%提高至41.1%(P=.027)。纳入多参数MRI和MRI-Bx结果后,73例中28例ADT时长增加、8例新增ADT推荐。
要点
- MRI-Bx较SOC-Bx显著提高Gleason评分7(6.7% vs 44.6%)和8-10(2.1% vs 38%)的比例。
- MRI-Bx使极高危患者比例从24.7%升至41.1%(P=.027)。
- 纳入MRI-Bx结果后,73例中28例ADT时长增加、8例新增ADT推荐。
核心结论
- 在接受放疗的患者中,MRI-Bx较SOC-Bx提高了阳性针芯百分比、Gleason评分和风险分组。
- 依据MRI-Bx结果强化治疗是否带来获益尚不明确。
研究设计与样本
- 单中心回顾性研究,纳入2008年1月至2016年1月接受放疗并同时行SOC-Bx和MRI-Bx的73例患者(其中47例既往有SOC-Bx)。
- 根据临床T分期、治疗前前列腺特异性抗原和Gleason评分进行NCCN风险分组并分配放疗或ADT推荐。
主要发现
- 与既往SOC-Bx相比,重复SOC-Bx和MRI-Bx常见Gleason评分升级:Gleason评分7为6.7% vs 44.6%(P<.001),Gleason评分8-10为2.1% vs 38%(P<.001)。
- MRI-Bx使极高危患者比例从24.7%升至41.1%(P=.027)。
- 与单独SOC-Bx相比,纳入MRI-Bx发现后病理阳性针芯百分比更高(均值37% vs 44%)。
- 纳入多参数MRI和MRI-Bx结果后,73例中28例ADT时长增加、8例新增ADT推荐。
关键数值与推荐
- Gleason评分7比例:既往SOC-Bx为6.7%,重复SOC-Bx和MRI-Bx为44.6%(P<.001)。
- Gleason评分8-10比例:既往SOC-Bx为2.1%,重复SOC-Bx和MRI-Bx为38%(P<.001)。
- 极高危患者比例:SOC-Bx为24.7%,MRI-Bx为41.1%(P=.027)。
- 病理阳性针芯百分比均值:单独SOC-Bx为37%,纳入MRI-Bx发现后为44%。
临床怎么用
- 对接受放疗的前列腺癌患者,MRI-Bx可提高Gleason评分和风险分组,可能影响ADT推荐。
- 依据MRI-Bx结果强化治疗是否获益尚不明确,临床决策需综合评估。
局限性
- 单中心回顾性研究,样本量73例。
- 依据MRI-Bx结果强化治疗的获益未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Targeted magnetic resonance imaging (MRI)/ultrasound fusion prostate biopsy (MRI-Bx) has recently been compared with the standard of care extended sextant ultrasound-guided prostate biopsy (SOC-Bx), with the former associated with an increased rate of detection of clinically significant prostate cancer. The present study sought to determine the influence of MRI-Bx on radiation therapy and androgen deprivation therapy (ADT) recommendations. METHODS AND MATERIALS: All patients who had received radiation treatment and had undergone SOC-Bx and MRI-Bx at our institution were included. Using the clinical T stage, pretreatment prostate-specific antigen, and Gleason score, patients were categorized into National Comprehensive Cancer Network risk groups and radiation treatment or ADT recommendations assigned. Intensification of the recommended treatment after multiparametric MRI, SOC-Bx, and MRI-Bx was evaluated. RESULTS: From January 2008 to January 2016, 73 patients received radiation therapy at our institution after undergoing a simultaneous SOC-Bx and MRI-Bx (n=47 with previous SOC-Bx). Repeat SOC-Bx and MRI-Bx resulted in frequent upgrading compared with previous SOC-Bx (Gleason score 7, 6.7% vs 44.6%; P<.001; Gleason score 8-10, 2.1% vs 38%; P<.001). MRI-Bx increased the proportion of patients classified as very high risk from 24.7% to 41.1% (P=.027). Compared with SOC-Bx alone, including the MRI-Bx findings resulted in a greater percentage of pathologically positive cores (mean 37% vs 44%). Incorporation of multiparametric MRI and MRI-Bx results increased the recommended use and duration of ADT (duration increased in 28 of 73 patients and ADT was added for 8 of 73 patients). CONCLUSIONS: In patients referred for radiation treatment, MRI-Bx resulted in an increase in the percentage of positive cores, Gleason score, and risk grouping. The benefit of treatment intensification in accordance with the MRI-Bx findings is unknown.
引用
- Reed A, Valle LF, Shankavaram U, et al. Effect of Prostate Magnetic Resonance Imaging/Ultrasound Fusion-guided Biopsy on Radiation Treatment Recommendations. Int J Radiat Oncol Biol Phys. 2016. PMID: 28333017. doi:10.1016/j.ijrobp.2016.12.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。